The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 31, 2025 for Aayush Agrawal, ....
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.8 pts more than Nifty Midcap 150 and 6.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aayush Agrawal, a promoter of Ajanta Pharma Limited (acting as trustee of the Aayush Agrawal Trust), has created a pledge on 1,27,660 shares, which is 0.10% of the company's total share capital, on December 30, 2025. The pledge is in favour of Bajaj Finance Ltd, and the stated reason is to increase a loan. After this creation, Aayush's total encumbered (pledged) shares stand at 82,48,407 shares, or 6.60% of share capital. The disclosure is filed under Regulation 31(1) and 31(2) of the SEBI (SAST) Regulations, 2011 with both BSE and NSE. No other promoter in the group is reporting any change in encumbrance status in this filing.
This is a small, routine pledge creation by one promoter to raise additional borrowing from Bajaj Finance. Since the pledged quantity is just 0.10% of capital and total promoter encumbrance remains low at 6.60%, it is unlikely to have any meaningful impact on the stock price, though investors generally monitor promoter pledge activity as a leverage signal.